Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2012, Article ID 690641, 8 pages
http://dx.doi.org/10.1155/2012/690641
Clinical Study

Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration

1Section of Ophthalmology and Visual Science, Department of Surgery, University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637, USA
2Department of Ophthalmology and Vision Science, University of California Davis Health System Eye Center, 4860 Y Street, Suite 2400 Sacramento, CA 95817, USA
3Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA

Received 16 April 2012; Revised 3 September 2012; Accepted 26 September 2012

Academic Editor: Chi-Chao Chan

Copyright © 2012 Seenu M. Hariprasad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. M. Brown, P. K. Kaiser, M. Michels et al., “Ranibizumab versus verteporfin for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 355, no. 14, pp. 1432–1444, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. C. D. Regillo, D. M. Brown, P. Abraham et al., “Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1,” American Journal of Ophthalmology, vol. 145, no. 2, pp. 239.e5–248.e5, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. D. S. Boyer, J. S. Heier, D. M. Brown, S. F. Francom, T. Ianchulev, and R. G. Rubio, “A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration,” Ophthalmology, vol. 116, no. 9, pp. 1731–1739, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. A. E. Fung, G. A. Lalwani, P. J. Rosenfeld et al., “An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration,” American Journal of Ophthalmology, vol. 143, no. 4, pp. 566.e2–583.e2, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. G. A. Lalwani, P. J. Rosenfeld, A. E. Fung et al., “A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study,” American Journal of Ophthalmology, vol. 148, no. 1, pp. 43.e1–58.e1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Spaide, “Ranibizumab according to need: a treatment for age-related macular degeneration,” American Journal of Ophthalmology, vol. 143, no. 4, pp. 679–680, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. D. F. Martin, M. G. Maguire, G. S. Ying, J. E. Grunwald, S. L. Fine, and G. J. Jaffe, “Ranibizumab and bevacizumab for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 364, no. 20, pp. 1897–1908, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Ikemori, A. Kato, T. Yasukawa et al., “Effect of a single-dose regimen of intravitreal ranibizumab in the treatment of neovascular age-related macular degeneration,” Journal of Clinical and Experimental Ophthalmology, vol. 3, p. 221, 2012. View at Google Scholar
  10. A. M. Carneiro, L. S. Mendonça, M. S. Falcão, S. L. Fonseca, E. M. Brandão, and F. M. Falcão-Reis, “Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting,” Clinical Ophthalmology, vol. 6, no. 1, pp. 1149–1157, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. O. P. Gupta, G. Shienbaum, A. H. Patel, C. Fecarotta, R. S. Kaiser, and C. D. Regillo, “A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact,” Ophthalmology, vol. 117, no. 11, pp. 2134–2140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. D. S. Boyer, A. N. Antoszyk, C. C. Awh, R. B. Bhisitkul, H. Shapiro, and N. R. Acharya, “Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration,” Ophthalmology, vol. 114, no. 2, pp. 246–252, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. P. K. Kaiser, D. M. Brown, K. Zhang et al., “Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results,” American Journal of Ophthalmology, vol. 144, no. 6, pp. 850.e4–857.e4, 2007. View at Publisher · View at Google Scholar · View at Scopus